411 related articles for article (PubMed ID: 23633392)
1. Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma.
Yust-Katz S; Liu D; Yuan Y; Liu V; Kang S; Groves M; Puduvalli V; Levin V; Conrad C; Colman H; Hsu S; Yung WK; Gilbert MR
Cancer; 2013 Aug; 119(15):2747-53. PubMed ID: 23633392
[TBL] [Abstract][Full Text] [Related]
2. Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513.
Brachman DG; Pugh SL; Ashby LS; Thomas TA; Dunbar EM; Narayan S; Robins HI; Bovi JA; Rockhill JK; Won M; Curran WP
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):961-7. PubMed ID: 25832688
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.
Robins HI; Zhang P; Gilbert MR; Chakravarti A; de Groot JF; Grimm SA; Wang F; Lieberman FS; Krauze A; Trotti AM; Mohile N; Kee AY; Colman H; Cavaliere R; Kesari S; Chmura SJ; Mehta M
J Neurooncol; 2016 Jan; 126(2):309-16. PubMed ID: 26508094
[TBL] [Abstract][Full Text] [Related]
4. A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma.
Gilbert MR; Gonzalez J; Hunter K; Hess K; Giglio P; Chang E; Puduvalli V; Groves MD; Colman H; Conrad C; Levin V; Woo S; Mahajan A; de Groot J; Yung WK
Neuro Oncol; 2010 Nov; 12(11):1167-72. PubMed ID: 20729242
[TBL] [Abstract][Full Text] [Related]
5. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Reardon DA; Vredenburgh JJ; Desjardins A; Peters K; Gururangan S; Sampson JH; Marcello J; Herndon JE; McLendon RE; Janney D; Friedman AH; Bigner DD; Friedman HS
J Neurooncol; 2011 Jan; 101(1):57-66. PubMed ID: 20443129
[TBL] [Abstract][Full Text] [Related]
6. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.
Groves MD; Puduvalli VK; Gilbert MR; Levin VA; Conrad CA; Liu VH; Hunter K; Meyers C; Hess KR; Alfred Yung WK
Br J Cancer; 2009 Aug; 101(4):615-20. PubMed ID: 19672263
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma.
Nghiemphu PL; Wen PY; Lamborn KR; Drappatz J; Robins HI; Fink K; Malkin MG; Lieberman FS; DeAngelis LM; Torres-Trejo A; Chang SM; Abrey L; Fine HA; Demopoulos A; Lassman AB; Kesari S; Mehta MP; Prados MD; Cloughesy TF;
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1422-7. PubMed ID: 20934264
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.
Hottinger AF; Ben Aissa A; Espeli V; Squiban D; Dunkel N; Vargas MI; Hundsberger T; Mach N; Schaller K; Weber DC; Bodmer A; Dietrich PY
Br J Cancer; 2014 May; 110(11):2655-61. PubMed ID: 24786603
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.
Desjardins A; Reardon DA; Peters KB; Threatt S; Coan AD; Herndon JE; Friedman AH; Friedman HS; Vredenburgh JJ
J Neurooncol; 2011 Dec; 105(3):601-6. PubMed ID: 21735117
[TBL] [Abstract][Full Text] [Related]
10. Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
Walbert T; Gilbert MR; Groves MD; Puduvalli VK; Yung WK; Conrad CA; Bobustuc GC; Colman H; Hsu SH; Bekele BN; Qiao W; Levin VA
J Neurooncol; 2011 Apr; 102(2):273-80. PubMed ID: 20652724
[TBL] [Abstract][Full Text] [Related]
11. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.
Brandes AA; Basso U; Reni M; Vastola F; Tosoni A; Cavallo G; Scopece L; Ferreri AJ; Panucci MG; Monfardini S; Ermani M;
J Clin Oncol; 2004 May; 22(9):1598-604. PubMed ID: 15117981
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma.
Kong DS; Lee JI; Kim JH; Kim ST; Kim WS; Suh YL; Dong SM; Nam DH
Neuro Oncol; 2010 Mar; 12(3):289-96. PubMed ID: 20167817
[TBL] [Abstract][Full Text] [Related]
13. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.
Jaeckle KA; Hess KR; Yung WK; Greenberg H; Fine H; Schiff D; Pollack IF; Kuhn J; Fink K; Mehta M; Cloughesy T; Nicholas MK; Chang S; Prados M;
J Clin Oncol; 2003 Jun; 21(12):2305-11. PubMed ID: 12805331
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.
Drappatz J; Norden AD; Wong ET; Doherty LM; Lafrankie DC; Ciampa A; Kesari S; Sceppa C; Gerard M; Phan P; Schiff D; Batchelor TT; Ligon KL; Young G; Muzikansky A; Weiss SE; Wen PY
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):85-90. PubMed ID: 20137866
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.
Perry JR; Bélanger K; Mason WP; Fulton D; Kavan P; Easaw J; Shields C; Kirby S; Macdonald DR; Eisenstat DD; Thiessen B; Forsyth P; Pouliot JF
J Clin Oncol; 2010 Apr; 28(12):2051-7. PubMed ID: 20308655
[TBL] [Abstract][Full Text] [Related]
16. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Krauze AV; Myrehaug SD; Chang MG; Holdford DJ; Smith S; Shih J; Tofilon PJ; Fine HA; Camphausen K
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):986-992. PubMed ID: 26194676
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study.
Prados MD; Yung WK; Fine HA; Greenberg HS; Junck L; Chang SM; Nicholas MK; Robins HI; Mehta MP; Fink KL; Jaeckle KA; Kuhn J; Hess KR; Schold SC;
Neuro Oncol; 2004 Jan; 6(1):33-7. PubMed ID: 14769138
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas.
Karavasilis V; Kotoula V; Pentheroudakis G; Televantou D; Lambaki S; Chrisafi S; Bobos M; Fountzilas G
J Neurol; 2013 Jun; 260(6):1469-80. PubMed ID: 23292205
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.
Brada M; Stenning S; Gabe R; Thompson LC; Levy D; Rampling R; Erridge S; Saran F; Gattamaneni R; Hopkins K; Beall S; Collins VP; Lee SM
J Clin Oncol; 2010 Oct; 28(30):4601-8. PubMed ID: 20855843
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy.
Quinn JA; Jiang SX; Reardon DA; Desjardins A; Vredenburgh JJ; Friedman AH; Sampson JH; McLendon RE; Herndon JE; Friedman HS
J Neurooncol; 2009 Dec; 95(3):393-400. PubMed ID: 19533023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
